Promoter Methylation of GATA4, WIF1, NTRK1 and Other Selected Tumour Suppressor Genes in Ovarian Cancer

被引：0
|
作者：
Chmelarova, M. [1 ]
Dvorakova, E. [2 ]
Spacek, J. [2 ]
Laco, J. [3 ,4 ]
Mzik, M. [1 ]
Palicka, V. [1 ]
机构：
[1] Charles Univ Prague, Fac Med Hradec Kralove, Inst Clin Biochem & Diagnost, CR-11636 Prague 1, Czech Republic
[2] Charles Univ Prague, Fac Med Hradec Kralove, Dept Obstet & Gyneacol, CR-11636 Prague 1, Czech Republic
[3] Charles Univ Prague, Fac Med Hradec Kralove, Fingerland Dept Pathol, CR-11636 Prague 1, Czech Republic
[4] Univ Hosp Hradec Kralove, Hradec Kralove 50005, Czech Republic
来源：
FOLIA BIOLOGICA | 2013年 / 59卷 / 02期
关键词：
MS-MLPA; DNA methylation; ovarian cancer; epigenetics; INHIBITORY FACTOR-I; LUNG-CANCER; HYPERMETHYLATION; CARCINOMAS; HEREDITARY; BRCA2;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer is the leading cause of death from gynaecologic tumours, but the molecular and especially epigenetic events underlying the transformation are poorly understood. Various methylation changes have been identified and show promise as potential cancer biomarkers. The aim of this study was to investigate promoter methylation of selected tumour suppressor genes in ovarian cancer by comparison with normal ovarian tissue. To search for epigenetic events we used methylation-specific multiplex ligation-dependent probe amplification to compare the methylation status of 44 tissue samples of ovarian cancer with 30 control samples. Using a 20% cut-off for methylation, we observed significantly higher methylation in genes NTKR1, GATA4 and WIF1 in the ovarian cancer group compared with the control group. These findings could potentially be used in screening of ovarian cancer, and may have implications for future chemotherapy based on epigenetic changes.
引用
收藏
页码：87 / 92
页数：6
相关论文
共 48 条
  • [31] Association Between Cyclin D1 Polymorphism with CpG Island Promoter Methylation Status of Tumor Suppressor Genes in Gastric Cancer
    Tomomitsu Tahara
    Tomoyuki Shibata
    Masakatsu Nakamura
    Hiromi Yamashita
    Daisuke Yoshioka
    Masaaki Okubo
    Joh Yonemura
    Yoshiteru Maeda
    Naoko Maruyama
    Toshiaki Kamano
    Yoshio Kamiya
    Hiroshi Fujita
    Yoshihito Nakagawa
    Mitsuo Nagasaka
    Masami Iwata
    Ichiro Hirata
    Tomiyasu Arisawa
    Digestive Diseases and Sciences, 2010, 55 : 3449 - 3457
  • [32] BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
    Ruscito, I.
    Dimitrova, D.
    Vasconcelos, I.
    Gellhaus, K.
    Schwachula, T.
    Bellati, F.
    Zeillinger, R.
    Benedetti-Panici, P.
    Vergote, I.
    Mahner, S.
    Cacsire-Tong, D.
    Concin, N.
    Darb-Esfahani, S.
    Lambrechts, S.
    Sehouli, J.
    Olek, S.
    Braicu, E. I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) : 2090 - 2098
  • [33] SRC-1 drives endocrine treatment-resistant breast cancer progression by silencing tumour suppressor genes through DNA methylation
    Ward, E.
    Vareslija, D.
    Fagan, A.
    Hill, A. D. K.
    Young, L.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 19 - 20
  • [34] Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer
    Jongsma, APM
    Piek, JMJ
    Zweemer, RP
    Verheijen, RHM
    Gebbinck, JWTK
    van Kamp, GJ
    Jacobs, IJ
    Shaw, P
    van Diest, PJ
    Kenemans, P
    JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2002, 55 (05): : 305 - 309
  • [35] Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGFβ1 epithelial–mesenchymal transition
    L. G. Kondratyeva
    A. A. Sveshnikova
    E. V. Grankina
    I. P. Chernov
    M. R. Kopantseva
    E. P. Kopantzev
    E. D. Sverdlov
    Doklady Biochemistry and Biophysics, 2016, 469 : 257 - 259
  • [36] Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGFβ1 epithelial-mesenchymal transition
    Kondratyeva, L. G.
    Sveshnikova, A. A.
    Grankina, E. V.
    Chernov, I. P.
    Kopantseva, M. R.
    Kopantzev, E. P.
    Sverdlov, E. D.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2016, 469 (01) : 257 - 259
  • [37] Immunohistochemical study of p16ink4α, Ki67 in combination with the study of the expression of miR-22, miR-92a and methylation of the promoter region of the WIF1 gene in the diagnosis of SIL and cervical squamous cell carcinoma
    Kogan, E.
    Demura, T.
    Bajramova, G.
    Chernova, V.
    Fajzullin, L.
    Fajzullina, N.
    Kiselev, V.
    VIRCHOWS ARCHIV, 2019, 475 : S318 - S318
  • [38] WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear
    Gourley, C
    Paige, AJW
    Taylor, KJ
    Scott, D
    Francis, NJ
    Rush, R
    Aldaz, CM
    Smyth, JF
    Gabra, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (06) : 1681 - 1689
  • [39] ALPHA-4, THE MAJOR REGULATORY PROTEIN OF HERPES-SIMPLEX VIRUS TYPE-1, IS STABLY AND SPECIFICALLY ASSOCIATED WITH PROMOTER-REGULATORY DOMAINS OF ALPHA-GENES AND OF SELECTED OTHER VIRAL GENES
    KRISTIE, TM
    ROIZMAN, B
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (10) : 3218 - 3222
  • [40] Exendin-4 exhibits a tumour suppressor effect in SKOVR-3 and OVACR-3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF-κB
    Khaleel, Eman F.
    Badi, Rehab M.
    Satti, Huda H.
    Mostafa, Dalia G.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (06) : 1092 - 1102
12345